Avicanna IncTSX: AVCN

Avicanna says 2022 was transformational despite challenging cannabis market

· Issued by Avicanna Inc

On 6ix: 6ix.com/news/avicanna-says-2022-was-transformational-despite-challenging-cannabis-market

Watch Avicanna's latest callAvicanna (TSX:AVCN) Q4 2025 Earnings Call · Replay · Apr 7Read the transcript of Avicanna (TSX:AVCN) Q4 2025 Earnings Call
Avicanna's next earnings callAvicanna (TSX:AVCN) Q3 2026 Earnings Call · Nov 12, 2026 at 8:30 AM ESTRegister

(NewsDirect)

Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022.

Azadian said 2022 was challenging for both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian said it was transformational year for Avicanna as it remained focused and deliver on its business plan.

Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across its four business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which contributed to successful exports to 18 international markets.

Watch the video on YouTube

Contact Details

Proactive USA

+1 347-449-0879

[email protected]

Copyright (c) 2023 TheNewswire - All rights reserved.

Avicanna Inc on 6ix

Earlier from Avicanna

Later from Avicanna

All Avicanna news releases